Larvol Delta - Testing-the-Combination-of-Anticancer-Drugs-ActimabA-and-Cemiplimab-REGN2810-to-Improve-Outcomes-for-Patients-With-Recurrent-Glioblastoma

Zamyl (lintuzumab) - Pfizer

Actimab-A (lintuzumab-Ac225) - Actinium Pharmaceuticals

Libtayo (cemiplimab-rwlc) - Regeneron

http://clinicaltrials.gov/ct2/show/NCT07422363

Jun 13, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next